Anixa Biosciences, Inc. – NASDAQ:ANIX
Anixa Biosciences stock price today
$3.04
+0.48
+18.75%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 1 hour
Anixa Biosciences stock price monthly change
-7.58%
month
Anixa Biosciences stock price quarterly change
-7.58%
quarter
Anixa Biosciences stock price yearly change
-35.02%
year
Anixa Biosciences key metrics
Market Cap | 83.02M |
Enterprise value | 141.93M |
P/E | -11.95 |
EV/Sales | N/A |
EV/EBITDA | -12.08 |
Price/Sales | N/A |
Price/Book | 5.45 |
PEG ratio | 111.49 |
EPS | -0.36 |
Revenue | N/A |
EBITDA | -12.92M |
Income | -11.59M |
Revenue Q/Q | -100% |
Revenue Y/Y | -99.99% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAnixa Biosciences stock price history
Anixa Biosciences stock forecast
Anixa Biosciences financial statements
| Jul 2023 | 0 | -2.51M | |
|---|---|---|---|
| Oct 2023 | 156K | -2.69M | -1724.36% |
| Jan 2024 | 0 | -3.25M | |
| Apr 2024 | 0 | -3.13M |
| Oct 2023 | 156K | -2.69M | -1724.36% |
|---|---|---|---|
| Jan 2024 | 0 | -3.25M | |
| Apr 2024 | 0 | -3.13M | |
| Oct 2025 | 0 | -3.51M |
Analysts Price target
Financials & Ratios estimates
| 2024-06-04 | -0.11 | -0.1 |
|---|---|---|
| 2024-09-06 | -0.11 | -0.1 |
| Jul 2023 | 26578000 | 1.99M | 7.5% |
|---|---|---|---|
| Oct 2023 | 25522000 | 2.15M | 8.43% |
| Jan 2024 | 25372000 | 1.76M | 6.97% |
| Apr 2024 | 24355000 | 1.77M | 7.28% |
| Jul 2023 | -1.44M | -980K | 3K |
|---|---|---|---|
| Oct 2023 | -1.96M | -593K | 279K |
| Jan 2024 | -2.30M | 129K | 2.26M |
| Apr 2024 | -1.45M | 556K | 897K |
Anixa Biosciences alternative data
| Aug 2023 | 4 |
|---|---|
| Sep 2023 | 4 |
| Oct 2023 | 4 |
| Nov 2023 | 4 |
| Dec 2023 | 4 |
| Jan 2024 | 4 |
| Feb 2024 | 4 |
| Mar 2024 | 4 |
| Apr 2024 | 4 |
| May 2024 | 4 |
| Jun 2024 | 4 |
| Jul 2024 | 4 |
Anixa Biosciences other data
100.00%
+88.03%
of ANIX is owned by hedge funds
27
-21
1.36M
-2.27M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jul 2023 | 5500 | 11800 |
| Mar 2024 | 40000 | 0 |
| Apr 2024 | 15009 | 0 |
| Jun 2024 | 49825 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | TITTERTON LEWIS H JR director | Common Stock | 405 | $2.7 | $1,094 | ||
Purchase | TITTERTON LEWIS H JR director | Common Stock | 7,102 | $2.66 | $18,891 | ||
Purchase | TITTERTON LEWIS H JR director | Common Stock | 330 | $2.6 | $858 | ||
Purchase | KUMAR AMIT officer: Chief Ex.. | Common Stock | 25,000 | $2.41 | $60,250 | ||
Purchase | KUMAR AMIT officer: Chief Ex.. | Common Stock | 25,000 | $2.41 | $60,250 | ||
Purchase | CATELANI MICHAEL officer: Presiden.. | Common Stock | 6,250 | $2.4 | $15,000 | ||
Purchase | TITTERTON LEWIS H JR director | Common Stock | 10,738 | $2.52 | $27,060 | ||
Purchase | TITTERTON LEWIS H JR director | Common Stock | 15,009 | $3.28 | $49,230 | ||
Purchase | BASKIES ARNOLD M director | Common Stock | 10,000 | $3.63 | $36,300 | ||
Purchase | KUMAR AMIT officer: Chief Ex.. | Common Stock | 30,000 | $3.22 | $96,600 |
-
What's the price of Anixa Biosciences stock today?
One share of Anixa Biosciences stock can currently be purchased for approximately $3.04.
-
When is Anixa Biosciences's next earnings date?
Unfortunately, Anixa Biosciences's (ANIX) next earnings date is currently unknown.
-
Does Anixa Biosciences pay dividends?
No, Anixa Biosciences does not pay dividends.
-
How much money does Anixa Biosciences make?
Anixa Biosciences has a market capitalization of 83.02M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 99.99% to 210K US dollars. Anixa Biosciences made a loss 9.81M US dollars in net income (profit) last year or -$0.1 on an earnings per share basis.
-
What is Anixa Biosciences's stock symbol?
Anixa Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "ANIX".
-
What is Anixa Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Anixa Biosciences?
Shares of Anixa Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Anixa Biosciences's key executives?
Anixa Biosciences's management team includes the following people:
- Dr. Amit Kumar Ph.D. Chairman, Pres & Chief Executive Officer(age: 61, pay: $720,870)
- Mr. Michael J. Catelani Chief Operating Officer, Chief Financial Officer & Corporation Sec.(age: 58, pay: $337,220)
-
How many employees does Anixa Biosciences have?
As Jul 2024, Anixa Biosciences employs 4 workers.
-
When Anixa Biosciences went public?
Anixa Biosciences, Inc. is publicly traded company for more then 41 years since IPO on 7 Oct 1983.
-
What is Anixa Biosciences's official website?
The official website for Anixa Biosciences is anixa.com.
-
Where are Anixa Biosciences's headquarters?
Anixa Biosciences is headquartered at 3150 Almaden Expressway, San Jose, CA.
-
How can i contact Anixa Biosciences?
Anixa Biosciences's mailing address is 3150 Almaden Expressway, San Jose, CA and company can be reached via phone at +40 87089808.
Anixa Biosciences company profile:
Anixa Biosciences, Inc.
anixa.comExchange:
NASDAQ
Full time employees:
4
Industry:
Biotechnology
Sector:
Healthcare
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
3150 Almaden Expressway
San Jose, CA 95118
San Jose, CA 95118
CIK: 0000715446
ISIN: US03528H1095
CUSIP: 03528H109
